понедельник, 25 января 2016 г.

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023


Novavax, Inc. , a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 . The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.



from Biotech News